HTFL
Heartflow Inc
$
34.490
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
35.300
Open
35.300
VWAP
34.50
Vol
230.94K
Mkt Cap
2.88B
Low
33.760
Amount
7.97M
EV/EBITDA(TTM)
--
Total Shares
83.40M
EV
3.77B
EV/OCF(TTM)
--
P/S(TTM)
--
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
Show More
5 Analyst Rating
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 36.60 USD with a low forecast of 35.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.490
Low
35.00
Averages
36.60
High
39.00
Current: 34.490
Low
35.00
Averages
36.60
High
39.00
Canaccord
Buy
maintain
$35 -> $39
2025-09-22
Reason
Canaccord
Price Target
$35 -> $39
2025-09-22
maintain
Buy
Reason
Canaccord raised the firm's price target on Heartflow to $39 from $35 and keeps a Buy rating on the shares. The firm updated its model following the release of its 10-Q and itsnew target reflects multiple expansion of the Elite Med-Tech comp group.
JPMorgan
Robbie Marcus
Overweight
initiated
$36
2025-09-02
Reason
JPMorgan
Robbie Marcus
Price Target
$36
2025-09-02
initiated
Overweight
Reason
JPMorgan analyst Robbie Marcus initiated coverage of Heartflow with an Overweight rating and $36 price target. The firm believes Heartflow is one of the "clearest and most pioneering downstream beneficiaries" of the artificial intelligence revolution in the healthcare sector. The company offers regulated healthcare and technology through its AI-enabled, diagnostic software for coronary artery disease, the analyst tells investors in a research note. JPMorgan says the company benefits from a capital-light business model with an "excellent" gross margin profile.
Piper Sandler
Matt O'Brien
Overweight
initiated
$38
2025-09-02
Reason
Piper Sandler
Matt O'Brien
Price Target
$38
2025-09-02
initiated
Overweight
Reason
Piper Sandler analyst Matt O'Brien initiated coverage of Heartflow with an Overweight rating and $38 price target. Heartflow is a commercial-stage medical technology company that provides artificial intelligence-powered software to diagnose and guide the treatment of coronary artery disease, the analyst tells investors in a research note. The firm believes the company remains in the early launch stages of the $2.9B plaque analysis market and is well positioned for continued share gains.
Stifel
Rick Wise
Buy
initiated
$35
2025-09-02
Reason
Stifel
Rick Wise
Price Target
$35
2025-09-02
initiated
Buy
Reason
Stifel analyst Rick Wise initiated coverage of Heartflow with a Buy rating and $35 price target. The firm believes the company's FFR CT and Plaque Analysis technology offers "meaningful value" for every coronary artery disease stakeholder. The company's plaque analysis technology reimbursement in January should drive growth and potentially position plaque analysis software as an incremental growth driver for 2026 and beyond, the analyst tells investors in a research note.
Canaccord
NULL -> Buy
initiated
$35
2025-09-02
Reason
Canaccord
Price Target
$35
2025-09-02
initiated
NULL -> Buy
Reason
Canaccord initiated coverage of Heartflow with a Buy rating and $35 price target. The firm believes the company's artificial intelligence-based products are positioned to change the standard of care in the detection of coronary artery disease. Heartflow has "compelling" clinical and economic data, which is beginning to be reflected in society guidelines and reimbursement in the U.S., the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
initiated
$35
2025-09-02
Reason
Morgan Stanley
Price Target
$35
2025-09-02
initiated
Equal Weight
Reason
Morgan Stanley initiated coverage of Heartflow with an Equal Weight rating and $35 price target. Heartflow is "a unique MedTech asset" as a pure-play AI and software company, but performance has been strong out of the gate with the stock up 60%-plus since the IPO on August 8, the analyst noted. While investor enthusiasm for the stock is "easy to understand," the firm believes the current valuation captures optimism around the company's opportunities.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Heartflow Inc (HTFL.O) is -53.81, compared to its 5-year average forward P/E of -49.77. For a more detailed relative valuation and DCF analysis to assess Heartflow Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-49.77
Current PE
-53.81
Overvalued PE
-39.70
Undervalued PE
-59.84
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-66.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-51.76
Undervalued EV/EBITDA
-81.15
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
17.59
Current PS
34.71
Overvalued PS
26.14
Undervalued PS
9.04
Financials
Annual
Quarterly
FY2025Q2
43.42M
Total Revenue
FY2025Q2
-13.72M
Operating Profit
FY2025Q2
-9.20M
Net Income after Tax
FY2025Q2
-0.11
EPS - Diluted
FY2025Q2
-28.09M
Free Cash Flow
FY2025Q2
75.48
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
-21.18
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
HTFL News & Events
Events Timeline
2025-10-22 (ET)
2025-10-22
08:16:39
Heartflow Launches Heartflow PCI Navigator
2025-09-22 (ET)
2025-09-22
16:14:25
Heartflow Receives FDA Approval for Plaque Analysis Algorithm and Cigna Coverage
2025-08-08 (ET)
2025-08-08
13:00:08
Heartflow opens at $28, IPO priced at $19 per share
Sign Up For More Events
Sign Up For More Events
News
8.5
17:16 PMBenzingaAlpha Acquisition: 118 Years of Discovering Transformative Investments
4.0
11-03NASDAQ.COMHTFL Surpasses Average Analyst Expectations
4.0
09-24NASDAQ.COMHTFL Surpasses Average Analyst Expectations
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
445.910
USD
-3.50%
MSFT
Microsoft Corp
497.100
USD
-1.98%
AAPL
Apple Inc
269.770
USD
-0.14%
META
Meta Platforms Inc
618.940
USD
-2.67%
AMZN
Amazon.com Inc
243.040
USD
-2.86%
AVGO
Broadcom Inc
355.590
USD
-0.94%
NVDA
NVIDIA Corp
188.080
USD
-3.65%
ORCL
Oracle Corp
243.800
USD
-2.60%
WMT
Walmart Inc
101.680
USD
+0.21%
XOM
Exxon Mobil Corp
114.500
USD
+0.72%
FAQ
What is Heartflow Inc (HTFL) stock price today?
The current price of HTFL is 34.49 USD — it has decreased -0.63 % in the last trading day.
What is Heartflow Inc (HTFL)'s business?
What is the price predicton of HTFL Stock?
What is Heartflow Inc (HTFL)'s revenue for the last quarter?
What is Heartflow Inc (HTFL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Heartflow Inc (HTFL)'s fundamentals?
How many employees does Heartflow Inc (HTFL). have?